The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 122-129

  Pretorius, M M ^a,b   Gainer, J V ^a,b   Van Guilder, G P ^a   Coelho, E B ^a   Luther, J M ^a   Fong, P ^a   Rosenbaum, D D ^b,c   Malave, H A ^b,c   Yu, C ^a   Ritchie, M D ^c   Vaughan, D E ^b,c   Brown, N J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; NITROPRUSSIDE SODIUM; RECEPTOR SUBTYPE;

ADULT; AFRICAN AMERICAN; ARTICLE; BRACHIAL ARTERY; ETHNICITY; EUROPEAN AMERICAN; FEMALE; FOREARM BLOOD FLOW; GENETIC POLYMORPHISM; GENOTYPE; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PULSE PRESSURE; RECEPTOR GENE; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ADULT; AFRICAN AMERICANS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOREARM; GENE FREQUENCY; GENOTYPE; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; NITROPRUSSIDE; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTOR, BRADYKININ B2; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 37549048609     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100250     Document Type: Article

References (35)

1. Mombouli, J.V. & Vanhoutte, P.M. Endothelial dysfunction: from physiology to therapy. J. Mol. Cell Cardiol. 31, 61-74 (1999).
2. Brown, N.J., Gainer, J.V., Stein, C.M. & Vaughan, D.E. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 33, 1431-1435 (1999).
3. Murakami, H. et al. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34, 164-170 (1999).
4. Hasan, A.A., Amenta, S. & Schmaier, A.H. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94, 517-528 (1996).
5. Gainer, J.V., Morrow, J.D., Loveland, A., King, D.J. & Brown, N.J. Effect of bradykinin-receptor blockade on the response to angiotensin- converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339, 1285-1292 (1998).
6. Witherow, F.N., Helmy, A., Webb, D.J., Fox, K.A. & Newby, D.E. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104, 2177-2181 (2001).
7. Sharma, J.N. Does the kinin system mediate in cardiovascular abnormalities? An overview. J. Clin. Pharmacol. 43, 1187-1195 (2003).
8. Braun, A., Maier, E., Kammerer, S., Muller, B. & Roscher, A.A. A novel sequence polymorphism in the promoter region of the human B2-bradykinin receptor gene. Hum. Genet. 97, 688-689 (1996).
9. Braun, A., Kammerer, S., Maier, E., Bohme, E. & Roscher, A.A. Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology 33, 32-35 (1996).
10. Lung, C.C., Chan, E.K. & Zuraw, B.L. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J. Allergy Clin. Immunol. 99(Part 1): 134-146 (1997).
11. Cui, J. et al. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J. Hypertens. 23, 55-62 (2005).
12. Gainer, J.V. et al. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am. J. Hypertens. 13, 1268-1273 (2000).
13. Wang, B., Dang, A. & Liu, G. Genetic variation in the promoter region of the beta2 bradykinin receptor gene is associated with essential hypertension in a Chinese Han population. Hypertens. Res. 24, 299-302 (2001).
14. Dhamrait, S.S. et al. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur. Heart J. 24, 1672-1680 (2003).
15. Brull, D. et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet 358, 1155-1156 (2001).
16. Hallberg, P. et al. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J. Hypertens. 21, 621-624 (2003).
17. Williams, A.G. et al. Bradykinin receptor gene variant and human physical performance. J. Appl. Physiol. 96, 938-942 (2004).
18. Bassett, D.R. Jr, Duey, W.J., Walker, A.J., Howley, E.T. & Bond, V. Racial differences in maximal vasodilatory capacity of forearm resistance vessels in normotensive young adults. Am. J. Hypertens. 5, 781-786 (1992).
19. Hinderliter, A.L. et al. Ethnic differences in forearm vasodilator capacity. Am. J. Cardiol. 78, 208-211 (1996).
20. Kalra, L. et al. Ethnic differences in arterial responses and inflammatory markers in Afro-Caribbean and Caucasian subjects. Arterioscler. Thromb. Vasc. Biol. 25, 2362-2367 (2005).
21. Meyer, A.C., Meyer, B.J., Morrison, J.F. & Pepler, W.J. Calcium, collagen, elastin and hexosamine levels in the arteries of whites and Bantu. S. Afr. Med. J. 39, 1017-1020 (1965).
22. Alfie, M.E., Sigmon, D.H., Pomposiello, S.I. & Carretero, O.A. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension. 29(Part 2): 483-487 (1997).
23. Madeddu, P. et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96, 3570-3578 (1997).
24. Madeddu, P. et al. Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice. Hypertension 35(Part 2): 391-396 (2000).
25. Weinberger, M.H. Salt sensitivity of blood pressure in humans. Hypertension 27(Part 2): 481-490 (1996).
26. Sagnella, G.A. Why is plasma renin activity lower in populations of African origin? J. Hum. Hypertens. 15, 17-25 (2001).
27. Ford, E.S., Giles, W.H., Myers, G.L. & Mannino, D.M. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. Clin. Chem. 49, 686-690 (2003).
28. Khera, A. et al. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 46, 464-469 (2005).
29. Haddad, E.B. et al. Post-transcriptional regulation of bradykinin B1 and B2 receptor gene expression in human lung fibroblasts by tumor necrosis factor-alpha: modulation by dexamethasone. Mol. Pharmacol. 57, 1123-1131 (2000).
30. Cardillo, C., Kilcoyne, C.M., Cannon, R.O. III & Panza, J.A. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 31, 1235-1239 (1998).
31. Rosenbaum, D.A. et al. Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin. Arterioscler. Thromb. Vasc. Biol. 22, 1023-1028 (2002).
32. Emanueli, C. et al. Dilated failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation 100, 2359-2365 (1999).
33. Silva, J.A. Jr et al. Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J. 14, 1858-1860 (2000).
34. Brown, N.J., Gainer, J.V., Murphey, L.J. & Vaughan, D.E. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102, 2190-2196 (2000).
35. Gainer, J.V., Stein, C.M., Neal, T., Vaughan, D.E. & Brown, N.J. Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity. Hypertension 37, 46-51 (2001).